`U.S. Patent No. 9,445,930
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________
`
`RESHAPE MEDICAL LLC et al.
`Petitioners
`v.
`
`FULFILLIUM, INC.
`Patent Owner
`
`
`Patent No. 9,445,930
`Issue Date: Sep. 20, 2016
`Title: METHODS, DEVICES, AND SYSTEMS FOR
`OBESITY TREATMENT
`_______________
`
`Inter Partes Review No. IPR2018-00958
`____________________________________________________________
`
`
`DECLARATION OF NICOLA A. PISANO, ESQ.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`RESHAPE 1019
`
`
`
`Case IPR2018-00958
`U.S. Patent No. 9,445,930
`
`
`I, Nicola A. Pisano, declare and state as follows:
`
`1.
`
`I am an attorney at law duly licensed in the States of California and
`
`New York and before the United States Patent and Trademark Office. I am a
`
`Partner at the law firm of Foley & Lardner LLP, lead counsel for ReShape Medical
`
`LLC in Fulfillium, Inc. v. ReShape Medical LLC et al., Civil Action No. 2:17-cv-
`
`08419-RGK-PLA (C.D. Cal.), and lead counsel in this Petition for Petitioners
`
`ReShape Medical LLC (“ReShape Medical”) and ReShape Lifesciences, Inc. I
`
`make this declaration based upon my personal knowledge, and if called upon to do
`
`so, I could and would competently testify to the matters stated herein.
`
`2.
`
`Foley & Lardner LLP was retained by ReShape Medical, Inc., in early
`
`2017 to respond to the original complaint by Fulfillium, Inc. in Fulfillium, Inc. v.
`
`ReShape Medical, Inc., Case No. 1:17-cv-00453-RGA (D. Del.). From the outset,
`
`ReShape Medical undertook a strategy to seek prompt resolution of that litigation,
`
`but to pursue Inter Partes Review of the ’915 and ’930 patents asserted in that
`
`complaint if no settlement were possible. As stated in my declaration filed May 7,
`
`2018, in the above litigation (D.I. 106-2), ReShape Medical undertook several
`
`unsuccessful efforts to negotiate resolution of the litigation, and delayed in filing
`
`its IPRs specifically so that the substantial filing costs could be allocated to
`
`settlement. See Exhibit 1020 at ¶¶ 2-3. When it became clear that Fulfillium had
`
`no interest in a negotiated resolution, I directed that the IPRs for the ’915 and ’930
`
`patents be filed on April 20, 2018.
`
`3.
`
`In early October 2017, I was informed that ReShape Medical had been
`
`acquired by Enteromedics, Inc. on October 3, 2017. In connection with that
`1
`
`
`
`RESHAPE 1019
`
`
`
`Case IPR2018-00958
`U.S. Patent No. 9,445,930
`
`acquisition, ReShape Medical, Inc. was first merged with a wholly-owned
`
`subsidiary of Enteromedics, Inc., named Nixon Subsidiary Holdings LLC, and the
`
`resulting company was then merged into another wholly-owned subsidiary of
`
`Enteromedics and renamed ReShape Medical LLC. On October 19, 2017,
`
`Enteromedics, Inc. changed its name to ReShape Lifesciences, Inc. My
`
`understanding is that the former shareholders of ReShape Medical, Inc. ultimately
`
`are responsible for the costs of this proceeding.
`
`5.
`
`Upon reviewing the Patent Owner’s Preliminary Response filed herein
`
`on August 8, 2018, I realized that although ReShape Lifesciences, Inc. was
`
`identified in the Notice of Each Real-Party-In-Interest it was not specifically
`
`labeled as a real-party-in-interest. I promptly contacted the Board to request
`
`permission to file an updated mandatory notice to correct the Notice of Each Real-
`
`Party-In-Interest to reflect that both ReShape Medical LLC and ReShape
`
`Lifesciences, Inc. are real-parties-in-interest.
`
`
`
`I declare under penalty of perjury that the foregoing is true and correct.
`
`Executed on August 29, 2018.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`By:
`
`
`
`
`/Nicola A. Pisano/
`Nicola A. Pisano
`Reg. No. 34,408
`
`
`
`
`
`
`2
`
`RESHAPE 1019
`
`
`
`Case IPR2018-00958
`U.S. Patent No. 9,445,930
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a true and correct copy of the
`
`Declaration of Nicola A. Pisano, Esq. is being filed on the PTAB E2E system and
`
`served on August 29, 2018 via electronic service to the following email addresses,
`
`and as consented in Paper 4.
`
`
`
`Gardella Grace P.A.
`455 Massachusetts Ave, NW, Suite 507
`Washington, DC 20001
`Telephone: 703-556-9600
`ggardella@gardellagrace.com
`info@gardellagrace.com
`ngrace@gardellagrace.com
`rdavila@gardellagrace.com
`
`
`
`By:
`
`
`
`
`
`
`
`
`
`
`
`/Nicola A. Pisano/
`Nicola A. Pisano
`Reg. No. 34,408
`Counsel for Petitioners
`
`4838-9170-1873
`
`3
`
`RESHAPE 1019
`
`